Publications

• Comprehensive molecular profiling of patients with pancreatic adenocarcinoma: A single institution’s experience.

  (Kamgar M, Dyson G, Diab M, Tesfaye AA, Korn WM, Shields AF, Philip AP.) Journal of Clinical Oncology . 36, no. 15_suppl.e16236 06/01/2018

• Total Neoadjuvant Therapy for Operable Pancreatic Cancer.

  (Kim RY, Christians KK, Aldakkak M, Clarke CN, George B, Kamgar M, Khan AH, Kulkarni N, Hall WA, Erickson BA, Evans DB, Tsai S.) Ann Surg Oncol. 2020 Sep 30 PMID: 33000372 SCOPUS ID: 2-s2.0-85091728559 10/02/2020

• Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable and borderline resectable pancreatic cancer.

  (Barnes CA, Aldakkak M, Christians KK, Clarke CN, Dua K, George B, Ritch PS, Kamgar M, Hall WA, Kulkarni N, Erickson BA, Evans DB, Tsai S.) Surgery. 2020 09;168(3):440-447 PMID: 32641278 SCOPUS ID: 2-s2.0-85087345792 07/10/2020

• Cost-effectiveness analysis of universal germline testing for patients with pancreatic cancer.

  (Krepline AN, Geurts JL, George B, Kamgar M, Madhavan S, Erickson BA, Hall WA, Griffin MO, Evans DB, Tsai S, Kim RY.) Surgery. 2020 Aug 18 PMID: 32826069 SCOPUS ID: 2-s2.0-85089521842 08/23/2020

• Targeted Therapies in Advanced Biliary Tract Cancer: An Evolving Paradigm.

  (Chakrabarti S, Kamgar M, Mahipal A.) Cancers (Basel). 2020 Jul 24;12(8) PMID: 32722188 PMCID: PMC7465131 07/30/2020

• Calcium Release-Activated Calcium (CRAC) Channel Inhibition Suppresses Pancreatic Ductal Adenocarcinoma Cell Proliferation and Patient-Derived Tumor Growth.

  (Khan HY, Mpilla GB, Sexton R, Viswanadha S, Penmetsa KV, Aboukameel A, Diab M, Kamgar M, Al-Hallak MN, Szlaczky M, Tesfaye A, Kim S, Philip PA, Mohammad RM, Azmi AS.) Cancers (Basel). 2020 Mar 22;12(3) PMID: 32235707 PMCID: PMC7140111 04/03/2020

• Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of Pancreatic Ductal Adenocarcinoma.

  (Azmi AS, Khan HY, Muqbil I, Aboukameel A, Neggers JE, Daelemans D, Mahipal A, Dyson G, Kamgar M, Al-Hallak MN, Tesfaye A, Kim S, Shidham V, M Mohammad R, Philip PA.) Clin Cancer Res. 2020 03 15;26(6):1338-1348 PMID: 31831564 PMCID: PMC7073299 SCOPUS ID: 2-s2.0-85081944777 12/14/2019

• PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors.

  (Mpilla G, Aboukameel A, Muqbil I, Kim S, Beydoun R, Philip PA, Mohammad RM, Kamgar M, Shidham V, Senapedis W, Baloglu E, Li J, Dyson G, Xue Y, El-Rayes B, Azmi AS.) Cancers (Basel). 2019 Nov 29;11(12) PMID: 31795447 PMCID: PMC6966587 12/05/2019

• Goals of Treatment Sequencing for Localized Pancreatic Cancer.

  (Evans DB, Kamgar M, Tsai S.) Ann Surg Oncol. 2019 Nov;26(12):3815-3819 PMID: 31493126 SCOPUS ID: 2-s2.0-85073126378 09/08/2019

• How I Treat Resectable Pancreatic Cancer With Adjuvant Therapy

  (PA Philip, M Kamgar.) Handbook of Gastrointestinal Cancers: Evidence-Based Treatment and Multidisciplinary Patient Care. PA Philip, M Kamgar (2019).'How I Treat Resectable Pancreatic Cancer With Adjuvant Therapy', in T Bekaii-Saab, B El-Rayes, T Pawlik (ed.) Handbook of Gastrointestinal Cancers: Evidence-Based Treatment and Multidisciplinary Patient Care: Springer Publishing Company, PP. 183-190 08/13/2019

• Protocols in genetic mice models of pancreatic cancer

  (Al-Qambar B, Chaker M, Kamgar M, Tesfaye A, Uwe-Wagner K, Azmi AS.) Animal Models in Cancer Drug Discovery. 17 April 2019:107-123 SCOPUS ID: 2-s2.0-85080860972 04/17/2019

• The evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities.

  (Tesfaye AA, Kamgar M, Azmi A, Philip PA.) Expert Rev Anticancer Ther. 2018 02;18(2):131-148 PMID: 29254387 PMCID: PMC6121777 SCOPUS ID: 2-s2.0-85043376842 12/20/2017